cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Fulcrum Therapeutics Inc
7 own
4 watching
Current Price
$0
$-0.6
(-4.68%)
logo-fulc
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
667.28M
52-Week High
52-Week High
24.79
52-Week Low
52-Week Low
3.21
Average Volume
Average Volume
0.71M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization667.28M
icon52-Week High24.79
icon52-Week Low3.21
iconAverage Volume0.71M
iconDividend Yield--
iconP/E Ratio--
What does the Fulcrum Therapeutics Inc do?
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Fulcrum Therapeutics Inc make?
News & Events about Fulcrum Therapeutics Inc.
Zolmax
9days ago
Fulcrum Therapeutics (NASDAQ:FULC Get Rating) had its price target trimmed by Oppenheimer from $30.00 to $26.00 in a report issued on Thursday, The Fly reports. FULC has been the subject of a number of other research reports. Morgan Stanley increased their target price on Fulcrum Therapeutics from $...
Globe Newswire
13days ago
CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the pricing of an underwritten public offering of 9,615,384 ...
Ticker Report
22days ago
Fulcrum Therapeutics, Inc. (NASDAQ:FULC Get Rating) major shareholder Ra Capital Management, L.P. purchased 180,703 shares of the businesss stock in a transaction dated Wednesday, January 4th. The stock was bought at an average cost of $7.28 per share, with a total value of $1,315,517...
Zolmax
1month ago
Fulcrum Therapeutics, Inc. (NASDAQ:FULC Get Rating) major shareholder Ra Capital Management, L.P. purchased 1,341,420 shares of the companys stock in a transaction dated Friday, December 16th. The stock was bought at an average cost of $5.42 per share, for a total transaction of $7,270,496.40. ...
Frequently Asked Questions
Frequently Asked Questions
What is Fulcrum Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Fulcrum Therapeutics Inc shares?
plus_minus_icon
How can I buy Fulcrum Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Fulcrum Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Fulcrum Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Fulcrum Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Fulcrum Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Fulcrum Therapeutics Inc?
plus_minus_icon
What percentage is Fulcrum Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Fulcrum Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.6
(-4.68%)
logo-fulc
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00